GLP1R and cardiac rhythm disease: Although GLP-1 RAs appear to have a neutral effect on cardiac arrhythmias, a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) by Thotamgari et al. indicated that linagliptin was associated with the highest proportion of AF events in diabetic patients.